Senior Editor, Consumer Health
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Malcolm Spicer
Innovus acquires Boston Topicals' ThermoMax hand warming cream in hot and warm formulations, BreastLife with amino acids to firm and lift women's breasts and HealthiFeet made with Knosis transdermal delivery system in a formulation firm says has been shown in a trial to increase temperature and blood flow in feet of diabetic patients. HealthiFeet will complement a product Innovus already offers and targets for consumers with diabetes, Diabases leg and foot relief topical.
Democrats potentially could target tightening regulatory oversight of some industries after regaining a majority in House, but Trump administration's high priority on reducing regulatory burdens bodes well that legislation to expand FDA's current authorities over the US supplement sector will not emerge before Congress' next session opens in 2021. NJ Democrat Frank Pallone could be member of Congress most commonly mentioned and lobbied by supplement industry during next session as Energy and Commerce chairman.
Company needs to get beyond a supply problem for products including iconic Bayer Aspirin brand and heat up Coppertone sun care and sunscreen product sales with line extensions to help drive the consumer health business to heights envisioned as part of an expansion a few years ago.
FTC proposes settlements with marketing and public relations firm Creaxion and Inside Publications over regulatory violations in advertising for Fit Organic Mosquito Repellent including failing to disclose US Olympic gymnasts as paid social medial endorsers and misrepresenting that paid commercial ads are opinions from an independent or objective publishers or sources.
Providing self-care products "opens this organization up to massive opportunity" which Perrigo will identify in early 2019, says new CEO Murray Kessler. It remains committed to selling or spinning off its Rx unit, though it's "just a few FDA approvals away from significantly" growing, he says as firm reports $68m net loss in its latest quarter.
Amphastar has initial inventory on hand of epinephrine inhalation aerosol reformulated with hydrofluoroalkane as a propellant, and expects "almost no costs" for sales of first several hundred thousand units. After two NDAs and two CRLs, firm convinces US FDA consumers can use the product without doctor or pharmacist guidance and understand it is not for ongoing asthma treatment.